Stokes Family Office, LLC
Family OfficePosition in GILD — Gilead Sciences, Inc.
CIK 1802278
NEW ORLEANS, LA
Position in GILD
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$224,379
-$93,384 QoQ
Shares Held
1,776
-22.1% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#1,852
of 2,266 holders
Holding Since
Dec 2022
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GILD Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Stokes Family Office, LLC holds $31,984,932 across 11 Drug Manufacturers - General names. GILD ranks #11 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
48,385 | $12,288,338 | |
| 2 | LLY |
ELI LILLY & Co
|
7,061 | $8,469,175 | |
| 3 | ABBV |
AbbVie Inc.
|
18,285 | $4,601,237 | |
| 4 | BMY |
Bristol Myers Squibb Co
|
34,624 | $1,995,034 | |
| 5 | AMGN |
Amgen Inc
|
5,143 | $1,862,383 | |
| 6 | MRK |
Merck & Co., Inc.
|
6,187 | $795,029 | |
| 7 | NVS |
Novartis AG
|
3,189 | $499,780 | |
| 8 | PFE |
Pfizer Inc
|
19,636 | $472,834 |
All Filings in GILD
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $224,379 | 1,776 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $317,763 | 2,280 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $335,448 | 2,733 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $236,319 | 2,129 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $230,831 | 2,082 | Shares | Sole | 2025-08-06 | |
| 2025-03-31 | $232,727 | 2,077 | Shares | Sole | 2025-05-13 | |
| 2023-06-30 | $200,844 | 2,606 | Shares | Other | 2023-08-14 | |
| 2023-03-31 | $204,355 | 2,463 | Shares | Other | 2023-05-08 | |
| 2022-12-31 | $230,078 | 2,680 | Shares | Other | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||